<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85609">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825850</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GBCL001</org_study_id>
    <nct_id>NCT01825850</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Irbesartan in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the drug interaction between Gemigliptin and
      Irbesartan by comparing pharmacokinetics of Gemigliptin and Irbesartan administered
      concomitantly and each alone in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate Cmax,ss of Gemigliptin and Irbesartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate AUCτ,ss of Gemigliptin and Irbesartan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate Cmin,ss of Gemigliptin and Irbesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate Tmax,ss of Gemigliptin, Irbesartan and LC15-0636 (active metaboilite of Gemigliptin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate Cmax,ss of LC15-0636 (active metaboilite of Gemigliptin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate AUCτ,ss of LC15-0636(active metabolite of Gemigliptin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic ratio</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate metabolic ratio of LC15-0636(active metabolite of Gemigliptin)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Gemigliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg q.d. during 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irbesartan 300mg q.d. during 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemiglitin + Irbesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <arm_group_label>Gemigliptin</arm_group_label>
    <arm_group_label>Gemiglitin + Irbesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_label>Gemiglitin + Irbesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria

               -  Age between 20 to 45, healthy male subjects (at screening)

               -  BMI between 18 - 27 kg/m2 (at screening)

               -  Blood pressure SBP 90-140 mmHg, DBP 60-95 mmHg

               -  FPG 70-125mg/dL glucose level (at screening)

               -  Subject who totally understand the progress of this clinical trials, make
                  decision by his free will, and signed a consent form to follow the

          -  Exclusion Criteria

               -  Subject who has past or present history of any diseases following below.(liver
                  including hepatitis virus carrier, kidney,
                  Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental
                  disorder.)

               -  Subject who had GI tract disease that influencable to drug absorption or(ulcer,
                  acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not
                  included)

               -  Subject who had drug hypersensitivity reaction.(gemigliptin, irbesartan,
                  aspirin, antibiotics)

               -  Subject who already admitted in other investigator product in 80 days

               -  Subject who had whole blood donation in 60 days, or component blood donation in
                  30 days or transfusion in 30 days currently
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>April 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
